<DOC>
	<DOCNO>NCT01586910</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy transcatheter aortic valve implantation ( TAVI ) patient severe , symptomatic Aortic Stenosis ( AS ) intermediate surgical risk randomize patient either Surgical Aortic Valve Replacement ( SAVR ) TAVI Medtronic CoreValve® System . Single Arm : The purpose trial evaluate safety effectiveness transcatheter aortic valve implementation ( TAVI ) patient sever symptomatic Aortic Stenosis ( AS ) intermediate surgical risk TAVI . This non-randomized phase pivotal clinical trial .</brief_summary>
	<brief_title>Safety Efficacy Study Medtronic CoreValve® System Treatment Severe , Symptomatic Aortic Stenosis Intermediate Risk Subjects Who Need Aortic Valve Replacement ( SURTAVI ) .</brief_title>
	<detailed_description />
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>Subject must comorbidities Heart Team agree predict risk operative mortality ≥3 % &lt; 15 % 30 day ( Intermediate Clinical Risk classification ) . Heart team evaluation clinical surgical mortality risk patient include calculated STS score predict risk surgical mortality augment consideration overall clinical status comorbidities unmeasured STS risk calculation ; Heart Team unanimously agree treatment proposal elgibility randomization* base clinical judgement ( include anatomy assessment , risk factor , etc . ) ; Subject severe aortic stenosis presenting ; 1 . Critical aortic valve area define initial aortic valve area ≤1.0cm2 aortic valve area index &lt; 0.6cm2/m2 AND 2 . Mean gradient &gt; 40mmHg Vmax &gt; 4m/sec rest echocardiogram simultaneous pressure recording cardiac catherization [ dobutamine stress , subject leave ventricular ejection fraction ( LVEF ) &lt; 55 % ] velocity ratio &lt; 0.25 ; Subject symptomatic his/her aortic valve stenosis , demonstrate New York Heart Association ( NYHA ) Functional Class II great ; Subject treat physician agree subject return require postprocedure followup visit ; Subject meet legal minimum age provide inform consent base local regulatory requirement ; Subject refuse surgical aortic valve replacement ( SAVR ) treatment option ; ( applicable Single Arm ) Any condition consider contraindication placement bioprosthetic valve ( i.e. , subject require mechanical valve ) ; A know hypersensitivity contraindication anticoagulation/antiplatelet regimen ( inability anticoagulated index procedure ) , nitinol , sensitivity contrast medium adequately premedicated ; Blood dyscrasia define : leukopenia ( WBC &lt; 1000mm3 ) , thrombocytopenia ( platelet count &lt; 50,000 cells/mm3 ) , history bleed diathesis coagulopathy ; Ongoing sepsis , include active endocarditis ; Any condition consider contraindication extracorporeal assistance ; Any percutaneous coronary peripheral interventional procedure perform within 30 day prior randomization* ( Subjects recent placement drug elute stent ( ) assess ability safely proceed SAVR within protocol timeframe ) ; Symptomatic carotid vertebral artery disease successful treatment carotid stenosis within six week randomization* ; Cardiogenic shock manifest low cardiac output , vasopressor dependence , mechanical hemodynamic support ; Recent ( within 6 month randomization* ) cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) ; Active gastrointestinal ( GI ) bleed would preclude anticoagulation ; Subject refuse blood transfusion ; Severe dementia ( result either inability provide inform consent trial/procedure , prevents independent lifestyle outside chronic care facility , fundamentally complicate rehabilitation procedure compliance followup visit ) ; Multivessel coronary artery disease Syntax score &gt; 22 and/or unprotected leave main coronary artery ( Syntax score calculation require patient history previous revascularization repeat revascularization plan ) ; Estimated life expectancy le 24 month due associate noncardiac comorbid condition ; Other medical , social , psychological condition opinion Investigator precludes subject appropriate consent adherence protocol require followup exam ; Currently participate investigational drug another device trial ( exclude registry ) ; Evidence acute myocardial infarction ≤30 day index procedure ; Need emergency surgery reason ; True porcelain aorta ( i.e . Heart Team agree aorta clampable SAVR ) ; Extensive mediastinal radiation ; Liver failure ( ChildC ) ; Reduced ventricular function leave ventricular ejection fraction ( LVEF ) &lt; 20 % measure resting echocardiogram ; Uncontrolled atrial fibrillation ( e.g . rest heart rate &gt; 120 bpm ) ; Pregnancy intent become pregnant prior completion protocol followup requirement ; End stage renal disease require chronic dialysis creatinine clearance &lt; 20 cc/min ; Pulmonary Hypertension ( systolic pressure &gt; 80mmHg ) ; Severe Chronic Obstructive Pulmonary Disease ( COPD ) demonstrate Forced Expiratory Volume ( FEV1 ) &lt; 750cc ; Frailty assessment identify : 1 . Subject &lt; 80 year age three follow apply 2 . Subject ≥ 80 year age two follow apply Wheelchair bind Resides institutional care facility ( e.g. , nursing home , skilled care center ) Body Mass Index &lt; 20 kg/m2 Grip Strength &lt; 16 kg Katz Index Score ≤ 4 Albumin &lt; 3.5 g/dL ; Marfan syndrome know connective tissue disease would necessitate aortic root replacement/intervention ; ( Not applicable Single Arm ) Note : Additional anatomical vascular exclusion criterion may apply . Note : * For purpose single arm phase trial , `` randomization '' refer trial enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>